Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 4/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | ADH5 | P11766 | 10/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.47 |
| ▸ | P4HA1 | P13674 | 2/20 | 0.46 |
| ▸ | P4HTM | Q9NXG6 | 2/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | APEX1 | P27695 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.45 |
| ▸ | MIF | P14174 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5280849 | 0.86 | CYP3A4 (0.60) | CYP3A4CYP1A2CYP2D6CYP2C19CYP2C9 | |
| SCHEMBL30317655 | 0.86 | CYP3A4 (0.62) | CYP3A4CYP1A2CYP2D6CYP2C19CYP2C9 | |
| SCHEMBL1976009 | 0.86 | CYP3A4 (0.62) | CYP3A4CYP1A2CYP2D6CYP2C19CYP2C9 | |
| SCHEMBL10759436 | 0.83 | ADH5 (0.50) | CYP3A4CYP1A2CYP2D6CYP2C19CYP2C9 | |
| SCHEMBL10469495 | 0.83 | CYP3A4 (0.54) | CYP3A4CYP1A2CYP2D6CYP2C19CYP2C9 | |
| SCHEMBL17352303 | 0.82 | HTT (0.65) | CYP3A4CYP1A2CYP2D6CYP2C19CYP2C9 | |
| SCHEMBL8297460 | 0.82 | CYP3A4 (0.56) | CYP3A4CYP1A2CYP2D6CYP2C19CYP2C9 | |
| SCHEMBL5306190 | 0.81 | CYP3A4 (0.55) | CYP3A4CYP1A2CYP2D6CYP2C19CYP2C9 | |
| SCHEMBL10757760 | 0.81 | CYP3A4 (0.55) | CYP3A4CYP1A2CYP2D6CYP2C19CYP2C9 | |
| SCHEMBL14822078 | 0.80 | LMNA (0.53) | CYP1A2CYP2C19CYP2C9LMNAP4HA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 125 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3856179-B1 | MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2026-05-13 | — | — | EP | disclosed |
| EP-4676547-A2 | ALPHA-SYNUCLEIN BINDERS AND METHODS OF USE | Merck Sharp & Dohme LLC (US) | 2026-01-14 | — | — | EP | disclosed |
| EP-4665331-A1 | ALPHA-SYNUCLEIN BINDERS AND METHODS OF USE | Merck Sharp & Dohme LLC (US) | 2025-12-24 | — | — | EP | disclosed |
| US-12297209-B2 | Benzodiazepine derivatives as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2025-05-13 | — | — | US | disclosed |
| EP-4077306-B1 | COMPOUNDS AND PROBES FOR IMAGING HUNTINGTIN PROTEIN | CHDI FOUNDATION INC (US) | 2025-05-07 | — | — | EP | disclosed |
| US-12268694-B2 | Combination pharmaceutical agents as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2025-04-08 | — | — | US | disclosed |
| US-20240360155-A1 | Benzodiazepine Derivatives as RSV Inhibitors | ENANTA PHARM INC (US) | 2024-10-31 | — | — | US | disclosed |
| US-20240327410-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2024-10-03 | — | — | US | disclosed |
| CN-113164458-B | Monoacylglycerol lipase modulators | 詹森药业有限公司 | 2024-09-13 | — | — | CN | disclosed |
| WO-2024186584-A2 | ALPHA-SYNUCLEIN BINDERS AND METHODS OF USE | MERCK SHARP & DOHME LLC (US) | 2024-09-12 | — | — | WO | disclosed |
| EP-1091958-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2001-04-18 | — | — | EP | disclosed |
| US-6140504-A | Substituted intermediate compounds for the preparation of n-[(aminoiminomethyl or aminomethyl)phenyl]propyl amides | AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) | 2000-10-31 | — | — | US | disclosed |
| US-6080767-A | Substituted n-[(aminoiminomethyl or aminomethyl)phenyl]propyl amides | AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) | 2000-06-27 | — | — | US | disclosed |
| EP-0986551-A1 | SULFONAMIDE DERIVATIVES, THEIR PRODUCTION AND USE | Takeda Pharmaceutical Company Limited (JP) | 2000-03-22 | — | — | EP | disclosed |
| WO-2000001692-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2000-01-13 | — | — | WO | disclosed |
| CN-1236358-A | Substituted N-[(aminoiminomethyl or aminomethyl) phenyl] propyl amides | RHONE POULENC RORER PHARMA (US) | 1999-11-24 | — | — | CN | disclosed |
| WO-1998054164-A1 | SULFONAMIDE DERIVATIVES, THEIR PRODUCTION AND USE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1998-12-03 | — | — | WO | disclosed |
| US-4954494-A | Cardiotonic and inotropic agents | RORER PHARMACEUTICAL CORPORATION (US) | 1990-09-04 | — | — | US | disclosed |
| WO-1989008108-A1 | PYRIDYL-PYRIDAZINONE AND PYRIDYL-PYRAZOLINONE COMPOUNDS AND THEIR USE IN THE TREATMENT OF CONGESTIVE HEART FAILURE | RORER INTERNATIONAL (OVERSEAS) INC. (US) | 1989-09-08 | — | — | WO | disclosed |
| US-4826835-A | INOTROPIC AGENTS | RORER PHARMACEUTICAL CORPORATION (US) | 1989-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240360155-A1 | Benzodiazepine Derivatives as RSV Inhibitors | GABRA5, GABRA1, GABBR2 | CYP3A4 24/4885CYP1A2 58/4885CYP2D6 82/4885 |
| US-12297209-B2 | Benzodiazepine derivatives as RSV inhibitors | GABRA5, GABRA1, GABBR2 | CYP3A4 24/4885CYP1A2 58/4885CYP2D6 82/4885 |
| US-12268694-B2 | Combination pharmaceutical agents as RSV inhibitors | ACE, ACE2, SPCS3 | CYP3A4 3234/4885CYP1A2 4518/4885CYP2D6 4511/4885 |
| US-20240327410-A1 | Monoacylglycerol Lipase Modulators | MGLL, LPL, PNLIP | CYP3A4 1831/4885CYP1A2 767/4885CYP2D6 625/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.